End points to establish the efficacy of new agents in the treatment of acute leukemia

Blood

Volumn 109, Issue 5, 2007, Pages 1810-1816

  Appelbaum, Frederick R ^a   Rosenblum, Daniel ^b   Arceci, Robert J ^c   Carroll, William L ^d   Breitfeld, Philip P ^e   Forman, Stephen J ^f   Larson, Richard A ^g   Lee, Stephanie J ^h   Murphy, Sharon B ⁱ   O'Brien, Susan ^j   Radich, Jerald ^a   Scher, Nancy S ^k   Smith, Franklin O ^l   Stone, Richard M ^h   Tallman, Martin S ^m  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; ASPARAGINASE; AZACITIDINE; CLOFARABINE; CYTARABINE; DASATINIB; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; LENALIDOMIDE; MERCAPTOPURINE; MITOXANTRONE; NELARABINE; RETINOIC ACID; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENETIC HETEROGENEITY; HUMAN; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; MYELODYSPLASIA; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT RESPONSE; UNITED STATES; VALIDATION STUDY;

EID: 33847347400     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-041152     Document Type: Review

References (40)

1. American Cancer Society. Cancer Facts and Figures 2006. http://www.cancer.org/downloads/STT/CAFF06EsCsMc.pdf. Accessed July 8, 2006.
2. SEER Cancer Statistics Review, 1975-2001. Ries LAG, Eisner MP, Kosary CL, et al, eds. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/ csr/1975_2003/. Accessed October 31, 2006.
3. Appelbaum FR. Acute myeloid leukemia in adults. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Clinical Oncology. Philadelphia, PA: Elsevier Churchill Livingstone; 2004:2825-2848.
4. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: a report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19:2054-2062.
5. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia. 2005;19:2101-2116.
6. Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
7. Kantarjian HM, Faderl S. Acute lymphoid leukemia in adults. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Clinical Oncology. Philadelphia, PA: Elsevier Churchill Livingstone; 2004:2793-2824.
8. A Guidance for Industry, Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. In: US Food and Drug Administration Center for Drug Evaluation and Research.1998. http://www.fda.gov/cder/guidance/1397fnl. pdf. Accessed October 31, 2006.
9. Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E III. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis. 1961;14:593-608.
10. Accelerated approval regulations. In: US Food and Drug Administration Center for Drug Evaluation and Research: Guidance for Industry Available Therapy, Chapter III.C. http://www.fda.gov/cder/guidance/5244fnl. htm#_Toc77574254, 2004. Accessed October 31, 2006.
11. Appelbaum FR. Impact of age on the biology of acute leukemia. In: Perry MC, ed. American Society of Clinical Oncology: 2005 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2005:528-532.
12. Hoelzer D, Gökbuget N. Treatment of elderly patients with acute lymphoblastic leukemia. In: Perry MC, ed. American Society of Clinical Oncology: 2005 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2005:533-539.
13. Tallman MS. Treatment of the older patient with acute myeloid leukemia. In: Perry MC, ed. American Society of Clinical Oncology: 2005 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2005:540-546.
14. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
15. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69-79.
16. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011-4020.
17. Wilson CS, Davidson GS, Martin SB, et al: Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108:685-96.
18. Leith CP, Chir B, Kopecky KJ, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997;89:3323-3329.
19. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025-2037.
20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [erratum appears in J Clin Oncol. 2004 Feb 1;22(3):576 Note: Lo-Cocco, Francesco [corrected to Lo-Coco, Francesco]. J Clin Oncol. 2003;21:4642-4649.
21. Sievers EL, Larson RA, Stadmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
22. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442-1452.
23. Estey EH, Garcia-Manero G, Giles FJ, Cortes J, O'Brien S, Kantarjian HM. Clinical relevance of CRp in untreated AML [abstract]. Blood. 2005;106 (part 1):161a. Abstract 541.
24. de Greef GE, van Putten WL, Boogaerts M, et al. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol. 2005;128:184-191.
25. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379-2386.
26. San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746-1751.
27. Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17:1566-1572.
28. Campana D, Neale GA, Coustan-Smith E, Pui CH. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience. Leukemia. 2001;15:278-279.
29. Coustan-Smith E, Gajjar A, Hijiya N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia. 2004;18:499-504.
30. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52-58.
31. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
32. Krejci O, van dV, V, Bader P, et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant. 2003;32:849-851.
33. de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2005;23:120-126.
34. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996;87:4789-4796.
35. Nemecek ER, Gooley TA, Woolfrey AE, Carpenter PA, Matthews DC, Sanders JE. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant. 2004;34:799-806.
36. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226-4235.
37. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128-135.
38. Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126-139.
39. Zittoun R, Achard S, Ruszniewski M. Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Psychooncology. 1999;8:64-73.
40. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMAAML 8A trial. Bone Marrow Transplant. 1997;20:307-315.